|
Shield Therapeutics PLC - Newcastle, England-based commercial-stage pharmaceutical company - Announces that the Korean Ministry of Food and Drug Safety has granted regulatory approval for Accrufer in South Korea for the treatment of iron deficiency in adult subjects. The approval follows submission of a new drug application by Korea Pharma in 2024 after the successful completion of a pharmacokinetic study. Shield is eligible to receive payments upon the first sale, as well as performance-based sales milestones and royalties on net sales. Chief Executive Anders Lundstrom said: ‘We are delighted with this approval of Accrufer in South Korea and commend Korea Pharma for their dedication and expertise throughout the regulatory process.’ Stock price: closed up 2.6% at 6.92 pence on Friday in London 12-month change: more than doubled from 2.75p on November 7, 2024 Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
